MXPA04001035A - Proceso para purificar n-[3-(3-cianopirazolo[1,5-a]pirimidin-7-il)fenil]-n-etilacetamida (zaleplon) y formas cristalinas de zaleplon accesibles con este proceso. - Google Patents

Proceso para purificar n-[3-(3-cianopirazolo[1,5-a]pirimidin-7-il)fenil]-n-etilacetamida (zaleplon) y formas cristalinas de zaleplon accesibles con este proceso.

Info

Publication number
MXPA04001035A
MXPA04001035A MXPA04001035A MXPA04001035A MXPA04001035A MX PA04001035 A MXPA04001035 A MX PA04001035A MX PA04001035 A MXPA04001035 A MX PA04001035A MX PA04001035 A MXPA04001035 A MX PA04001035A MX PA04001035 A MXPA04001035 A MX PA04001035A
Authority
MX
Mexico
Prior art keywords
zaleplon
purification
crystalline forms
regioisomer
byproduct
Prior art date
Application number
MXPA04001035A
Other languages
English (en)
Inventor
Singer Claude
Original Assignee
Biogal Gyogyszergyar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/170,673 external-priority patent/US6884888B2/en
Application filed by Biogal Gyogyszergyar filed Critical Biogal Gyogyszergyar
Publication of MXPA04001035A publication Critical patent/MXPA04001035A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)

Abstract

Se revela un proceso de purificacion que es capaz de separar zaleplon y un regioisomero de zaleplon que tiende a formarse como un subproducto en la sintesis quimica de zaleplon, que deriva en zaleplon esencialmente puro. Ademas, formas cristalinas novedosas de zaleplon son accesibles con el proceso.
MXPA04001035A 2001-08-01 2002-08-01 Proceso para purificar n-[3-(3-cianopirazolo[1,5-a]pirimidin-7-il)fenil]-n-etilacetamida (zaleplon) y formas cristalinas de zaleplon accesibles con este proceso. MXPA04001035A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30939101P 2001-08-01 2001-08-01
US31790701P 2001-09-06 2001-09-06
US38819902P 2002-06-12 2002-06-12
US10/170,673 US6884888B2 (en) 2001-06-12 2002-06-12 Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon)
PCT/US2002/024553 WO2003011228A2 (en) 2001-08-01 2002-08-01 Purification and crystalline forms of zaleplon

Publications (1)

Publication Number Publication Date
MXPA04001035A true MXPA04001035A (es) 2004-06-22

Family

ID=27496922

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001035A MXPA04001035A (es) 2001-08-01 2002-08-01 Proceso para purificar n-[3-(3-cianopirazolo[1,5-a]pirimidin-7-il)fenil]-n-etilacetamida (zaleplon) y formas cristalinas de zaleplon accesibles con este proceso.

Country Status (14)

Country Link
US (2) US6852858B2 (es)
EP (1) EP1430054A4 (es)
JP (1) JP2005523874A (es)
CA (1) CA2453751A1 (es)
CZ (1) CZ200471A3 (es)
HR (1) HRP20040180A2 (es)
HU (1) HUP0402253A3 (es)
IL (1) IL160076A0 (es)
IS (1) IS7128A (es)
MX (1) MXPA04001035A (es)
NO (1) NO20040887L (es)
PL (1) PL374176A1 (es)
SK (1) SK472004A3 (es)
WO (1) WO2003011228A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1305315A2 (en) * 2000-08-03 2003-05-02 Wyeth Polymorphs of zaleplon and methods for the preparation thereof
TR200402588T3 (tr) * 2001-06-12 2004-11-22 Biogal Gyogyszergyar Rt N-[3-(3-siyanopirazolo[1,5-A]pirimidin-7-il)fenil]-N- etilasetamidin(zaleplon) üretim işlemi
US20050032818A1 (en) * 2001-06-12 2005-02-10 Entire Interest N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl]-N-ethylacetamide and crystalline forms of zaleplon
JP2005523874A (ja) * 2001-08-01 2005-08-11 テバ ジョジセルジャール レースベニュタールシャシャーグ Ｎ−〔３−（３−シアノピラゾロ〔１，５−ａ〕ピリミジン−７−イル）フェニル〕−Ｎ−エチルアセタミド（ザレプロン）の精製方法、及び当該方法により得られうるザレプロンの結晶型
ZA200406577B (en) * 2002-02-15 2006-06-28 Teva Gyogyzeryan Reszvenytarsa Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
CZ20023575A3 (cs) * 2002-10-25 2004-01-14 Léčiva, A.S. Způsob výroby N-ethyl-N-[3-(3-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-fenyl]-acetamidu (zaleplonu)
DE112004001615T5 (de) 2003-09-04 2006-06-14 Cipla Ltd. Zaleplon-Synthese
JP2007517876A (ja) * 2004-01-14 2007-07-05 マリンクロッド・インコーポレイテッド 選択的ピラゾロピリミジン類の合成のための２相法
HUP0400325A3 (en) * 2004-02-02 2005-11-28 Richter Gedeon Vegyeszet Pure n-[3-(-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethyl-acetamide, process for its preparation and intermediates
JPWO2006062129A1 (ja) * 2004-12-08 2008-06-12 株式会社クラレ （５α，７α）−３−スピロ−２’−（１’，３’−ジオキソラン）−２４−オキソコレスト−２２−エン−７−イルベンゾアートの製造方法
WO2007043939A1 (en) * 2005-10-07 2007-04-19 Astrazeneca Ab Novel crystalline form of 3,5-dibromo-n- [(2s)-2-(-4-fluorophenyl)-4-(3-morpholin-4-ylazetidin-1-yl)butyl] -n-methylbenzamide, modification a
US7761955B1 (en) * 2007-08-30 2010-07-27 Hiltz Erik D Dual port cleaning and extraction apparatus
US8171598B1 (en) 2010-07-26 2012-05-08 Erik Daniel Hiltz Dual port cleaning and extraction apparatus
TW201946625A (zh) 2013-11-15 2019-12-16 美商阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626538A (en) 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US5714607A (en) 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
DE10004790B4 (de) 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
WO2001078725A2 (en) 2000-04-13 2001-10-25 Synthon B.V. Modified release formulations containing a hypnotic agent
EP1305315A2 (en) 2000-08-03 2003-05-02 Wyeth Polymorphs of zaleplon and methods for the preparation thereof
AR029780A1 (es) 2000-12-13 2003-07-16 Gador Sa Procedimiento mejorado para la obtencion de n-[3(3-ciano-pirazolo[1,5-a]pirimidin-7-il)fenil]-n-etil-acetamida
TR200402588T3 (tr) 2001-06-12 2004-11-22 Biogal Gyogyszergyar Rt N-[3-(3-siyanopirazolo[1,5-A]pirimidin-7-il)fenil]-N- etilasetamidin(zaleplon) üretim işlemi
JP2005523874A (ja) 2001-08-01 2005-08-11 テバ ジョジセルジャール レースベニュタールシャシャーグ Ｎ−〔３−（３−シアノピラゾロ〔１，５−ａ〕ピリミジン−７−イル）フェニル〕−Ｎ−エチルアセタミド（ザレプロン）の精製方法、及び当該方法により得られうるザレプロンの結晶型
EP1476446B1 (de) * 2002-02-14 2007-08-01 Cilag AG Verfahren zur herstellung von n-ethyl-n-(3-(3-cyanopyrazolo-(1,5-a)-pyrimidin-7-yl)phenyl)-acetamid
PL207322B1 (pl) 2002-05-14 2010-11-30 Adamed Społka Z Ograniczoną Odpowiedzialnością Sposób wytwarzania zaleplonu
CZ20023575A3 (cs) * 2002-10-25 2004-01-14 Léčiva, A.S. Způsob výroby N-ethyl-N-[3-(3-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-fenyl]-acetamidu (zaleplonu)

Also Published As

Publication number Publication date
US20050065168A1 (en) 2005-03-24
PL374176A1 (en) 2005-10-03
EP1430054A2 (en) 2004-06-23
HUP0402253A3 (en) 2005-12-28
HUP0402253A2 (hu) 2005-02-28
WO2003011228A2 (en) 2003-02-13
US7348429B2 (en) 2008-03-25
US6852858B2 (en) 2005-02-08
CA2453751A1 (en) 2003-02-13
SK472004A3 (en) 2004-12-01
NO20040887L (no) 2004-02-27
EP1430054A4 (en) 2005-06-22
CZ200471A3 (cs) 2004-11-10
WO2003011228A3 (en) 2003-10-30
IL160076A0 (en) 2004-06-20
US20030130291A1 (en) 2003-07-10
JP2005523874A (ja) 2005-08-11
HRP20040180A2 (en) 2004-12-31
IS7128A (is) 2004-01-28

Similar Documents

Publication Publication Date Title
MXPA04001035A (es) Proceso para purificar n-[3-(3-cianopirazolo[1,5-a]pirimidin-7-il)fenil]-n-etilacetamida (zaleplon) y formas cristalinas de zaleplon accesibles con este proceso.
UA95083C2 (ru) Азеотропная или близкая к азеотропной композиции, которые содержат 1,1,1,2,3-пентафторопропен и фтороводород, способы отделения и получения 1,1,1,2,3-пентафторопропена
ZA200410000B (en) Method for producing C13-alcohol mixtures
AU2003214132A1 (en) (meth)acrylic acid crystal and method for the production and purification of aqueous (meth)acrylic acid
AU2003221872A1 (en) Process for purification of anhydrous hydrogen chloride gas
AU2003205330A1 (en) Non-oxidative conversion of gas to liquids
MXPA05012362A (es) Yodopirazolilcarboxanilidas.
MXPA02010565A (es) Produccion de policetidos.
AU2003277276A8 (en) Improved production of bacterial strains cross reference to related applications
NO20061828L (no) Nye derivater av 4A,5,9,10,11,12-heksahydrobenzofuro[3A,3,2][2]-benzazepin, fremgangsmate for fremstilling derav og anvendelse derav ved fremstilling av medikamenter
EA200700139A1 (ru) Способ отделения и очистки цезия-131 от карбоната бария
IL165988A0 (en) Process for the preparation of fibrinogen
AP2004003091A0 (en) Process for the preparation of high purity perindopril and intermediates useful in the synthesis
MX2007002808A (es) Proceso para el aislamiento de tacrolimus cristalino.
SG86468A1 (en) Production process of high-purity gypsum
MY124538A (en) Process for the further purification of hydrogen peroxide solutions
WO2008041261A3 (en) Process and device for the production of high-purity silicon using multiple precursors
AU2003295670A8 (en) Integrated gas to olefins process with recovery and conversion of by-products
WO2007026376A3 (en) A novel process for preparation of highly pure crystalline hydrochlorothiazide
NO20032469D0 (no) Krystallisasjonsprosess for fremstilling av sterk konsentrert hydrogenperoksid
MXPA03010548A (es) Proceso para el aislamiento de imipenem cristalino.
MXPA04004980A (es) Antagonistas del receptor ccr-3.
MY139289A (en) Process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
SI1704140T1 (sl) Postopek za pripravo (R)-5-(2-aminopril)-2-metoksibenzensulfonamida
AP1511A (en) Process for the isolation of crystalline imipenem.